CYTO Reductive Surgery in Kidney Cancer Plus Immunotherapy and Targeted Kinase Inhibition

This study is investigating whether removing the primary kidney tumor through surgery, combined with immunotherapy and a targeted drug, can improve outcomes for people with advanced kidney cancer that has spread to other parts of the body. Researchers want to know if taking out the main tumor first helps these combination treatments work better. **You may be eligible if...** - You are 18 years or older - You have been diagnosed with kidney cancer (clear cell type) that has spread to other organs - You have not yet received any treatment for your metastatic kidney cancer - Your primary tumor in the kidney is measurable on scans - You are in good physical condition (ECOG 0–1) - You are using effective contraception if you are of childbearing potential **You may NOT be eligible if...** - You have already received treatment for metastatic kidney cancer - You have a non-clear cell type of kidney cancer - Your organ function (blood, liver, kidney, heart) does not meet minimum levels - You are pregnant Talk to your doctor to see if this trial is right for you.